|
業務類別
|
Biotechnology |
|
業務概覽
|
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations,acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need. |
| 公司地址
| 60 First Street, Cambridge, MA, USA, 02141 |
| 電話號碼
| +1 617 465-0013 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.primemedicine.com |
| 員工數量
| 146 |
| Dr. Ann L. Lee, PhD |
Chief Technical Officer |
美元 505.38K |
23/04/2026 |
| Ms. Carman Alenson |
Senior Vice President, Finance and Chief Accounting Officer |
-- |
03/03/2026 |
| Dr. Allan Reine, M.D. |
Director and Chief Executive Officer |
美元 606.21K |
16/04/2026 |
| Ms. Svetlana Makhni |
Chief Financial Officer |
-- |
16/04/2026 |
|
|
| Dr. Wendy K. Chung, M.D.,PhD |
Independent Director |
23/04/2026 |
| Dr. Thomas Cahill, M.D.,PhD |
Independent Director |
23/04/2026 |
| Dr. David P. Schenkein, M.D. |
Independent Director |
23/04/2026 |
| Mr. Robert Taylor Nelsen |
Independent Director |
23/04/2026 |
| Ms. Kaye Foster |
Independent Director |
23/04/2026 |
| Mr. Michael A. Kelly |
Independent Director |
23/04/2026 |
| Mr. Jeffrey D. Marrazzo |
Executive Chairman of the board |
23/04/2026 |
| Dr. Allan Reine, M.D. |
Director and Chief Executive Officer |
16/04/2026 |
|
|
|
|
